NeuroOne Medical Technologies Corporation Q3 2026 Earnings Call Summary

NeuroOne Medical Technologies Corporation Q3 2026 Earnings Call Summary

Moby Intelligence

Fri, August 14, 2026 at 3:49 AM GMT+3 3 min read

• NMTC +6.01%

Strategic Performance and Operational Drivers

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Revenue growth of 16% was driven by strong demand for the OneRF Brain Ablation System, though recognized revenue was constrained by manufacturing lead times.

• Gross margins expanded to 59.9% due to a favorable product mix, reflecting the company's focus on higher-margin disposable components.

• The receipt of ISO 13485 certification serves as a critical strategic gateway, enabling the company to enter international markets with its diagnostic and ablation product lines.

• Management attributed the current order backlog to 6-month supplier lead times and shifts in product mix that exceeded existing manufacturing flexibility.

• The StereoCED platform is positioned to address the 'commercial risk' of complex neurosurgical workflows by leveraging existing hospital equipment and robotic-assisted multi-trajectory delivery.

• Strategic focus for the Trigeminal Nerve Ablation System involves a hybrid commercialization model using internal personnel and independent distributors to target 30 high-volume centers.

• Clinical validation was bolstered by a Mayo Clinic study confirming that OneRF procedures can be performed safely in patients with existing neuromodulation implants, expanding the addressable patient pool.

Strategic Outlook and Guidance Assumptions

• Fiscal 2026 recognized revenue guidance of $9.2 million to $10.5 million is contingent on the timing of shipments and supplier ability to meet the $11.2 million order demand.

• Qualification of a second, larger manufacturing site is expected to go online in early 2027 to increase capacity, reduce lead times, and improve responsiveness to product mix changes.

• The company anticipates submitting a 510(k) for the Basivertebral Nerve Ablation (BVNA) system in the second half of calendar 2027, leveraging the existing OneRF generator infrastructure.

• StereoCED is projected to be ready for investigational human clinical studies by late September 2026, with initial device sales to pharmaceutical partners expected later this year.

• International expansion strategy involves collaborating with Zimmer Biomet for specific geographies while exploring independent partnerships for territories where NeuroOne retains exclusivity.

Structural and Risk Factors

• A 1-for-6 reverse stock split was implemented in April 2026 to maintain compliance and adjust the company's capital structure.

• The company utilized its at-the-market (ATM) offering program twice in 2026, raising $1.4 million total to support working capital requirements.

• Lead investor holdings increased from 7.4% to 12.5% following the quarter, signaling strengthened internal support despite market volatility.

• Manufacturing concentration risk is being addressed through the second site qualification to mitigate the impact of the current 6-month lead time bottleneck.

Q&A Session Highlights

Manufacturing backlog resolution and second site timeline

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

• Management explained that the backlog stems from 6-month lead times and build-to-order constraints that make responding to small product mix changes inefficient.

• The second manufacturing site, expected in early 2027, will be significantly larger and is the primary strategy for addressing long-term capacity issues without sacrificing margins.

International distribution strategy and ISO certification impact

• ISO certification allows for immediate registration in geographies that recognize FDA clearance, while others like Europe will require additional clinical data.

• NeuroOne will meet with Zimmer Biomet next quarter to finalize which international territories the partner will target first versus which ones NeuroOne will manage independently.

StereoCED adoption in clinical versus commercial stages

• Management noted that while pharmaceutical companies rarely switch delivery devices mid-trial (Phase II/III), StereoCED is being positioned for new preclinical starts and as a post-approval 510(k) bridge for existing therapies.

• The platform aims to solve the '8 to 12 hour' procedure time bottleneck currently associated with brain-delivered therapeutics.

Trigeminal Nerve Ablation commercialization and Zimmer Biomet relationship

• Management clarified that using independent distributors for Trigeminal Neuralgia does not indicate a lack of interest from Zimmer Biomet; rather, it allows NeuroOne to move forward while Zimmer focuses on the larger Brain Ablation opportunity.

• Current Trigeminal sales have been intentionally limited to prioritize manufacturing capacity for the higher-volume OneRF Brain Ablation orders.